Oragenics Inc. filings document the regulatory record of a clinical-stage biotechnology company focused on intranasal CNS therapeutics. The company’s 8-K reports include clinical and regulatory disclosures for ONP-002, including materials related to its Phase IIa program for concussion and mild traumatic brain injury, along with Regulation FD presentations and other public updates.
The filing record also covers capital-structure matters such as at-the-market common stock sales arrangements, shareholder meeting and proposal deadlines, executive compensation and equity awards, governance matters, risk factors, operating results and financial-condition disclosures, including going-concern language in the annual report.
A holder of OGEN common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 210 shares of common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of 191.94. The shares relate to an issuer that had 4,168,223 shares outstanding at the time stated. The seller acquired 171 shares as restricted stock units on 06/17/2022 and 39 shares as restricted stock units on 11/20/2020, both described as compensation from the issuer.
Oragenics, Inc. filed a current report to note that it has issued a new press release for shareholders. On November 12, 2025, the company released an update describing recent developments that took place during the third quarter of 2025 and shortly afterward. The report states that this press release is being furnished as an exhibit and incorporated by reference, directing readers to that document for the detailed business and operational update.
Oragenics (OGEN) filed its Q3 2025 10‑Q, reporting a net loss of $3.07 million for the quarter and $7.56 million year‑to‑date. Operating expenses were driven by higher G&A tied to legal and financing activity, including a $700,000 accrual for a legal settlement, while R&D rose modestly as the company prepared ONP‑002 for clinical work.
Liquidity improved significantly: cash and equivalents were $11.4 million as of September 30, 2025, reflecting a July financing of $15.2 million in net proceeds from 660,000 Series H preferred shares and accompanying warrants, and repayment of a $3.0 million short‑term note. Stockholders’ equity stood at $9.83 million. The company effected a 1‑for‑30 reverse split in June and regained NYSE American equity compliance in October.
Management continues to note substantial doubt about the company’s ability to continue as a going concern, though current cash is expected to fund operations for at least the next twelve months and support the planned ONP‑002 Phase 2a start.
Oragenics, Inc. entered a Settlement Agreement with Ladenburg Thalmann, paying $700,000 for a mutual release of all claims related to a disputed fee tied to a prior asset purchase. This resolves arbitration between the parties.
The company also regained compliance with NYSE American continued listing standards, and the “.BC” indicator is expected to be removed at the open on October 21, 2025. Oragenics reports that stockholders’ equity exceeds $6.0 million as of October 18, 2025, satisfying Sections 1003(a)(i), (ii) and (iii).
Management cites recent financing actions: in July 2025, a public offering of Series H Convertible Preferred Stock generated $16.5 million in gross proceeds and is initially convertible into up to 9,570,000 shares of common stock, inclusive of dividends payable on the Series H Preferred Stock. Additional capital included an ATM sale on February 5, 2025 for $2.75 million gross and a September 2024 offering for $4.45 million gross.
Oragenics, Inc. appointed Natasha Giordano to its board of directors, effective September 1, 2025. She brings extensive leadership experience from prior CEO and board roles at multiple pharmaceutical and healthcare-related companies and holds a Bachelor of Science in nursing from Wagner College.
Under Oragenics’ non-employee director compensation program, which provides a $45,000 annual base fee for board service, the board agreed to pay Ms. Giordano $3,750 per month for September through December 2025. The company states there are no special arrangements or related-party transactions tied to her appointment, and she has agreed to stand for re-election at the next annual shareholder meeting.
Oragenics Inc. reporting person Natasha Giordano filed an Initial Statement of Beneficial Ownership (Form 3) related to a 09/01/2025 event. The filing lists Giordano's address in Sarasota, FL and indicates her relationship to the issuer as a Director. The form states no securities are beneficially owned by Giordano as of the filing. The document is signed by an attorney-in-fact on behalf of Giordano on 09/02/2025.
Oragenics, Inc. (OGEN) filed a Registration Statement on Form S-8 covering employee benefit plans and incorporated multiple prior registration statements and amendments by reference. The filing lists related Annual and Quarterly Reports filed through August 11, 2025, includes signatures by officers and directors dated August 25, 2025, and enumerates corporate governance and equity-plan documents and amendments being incorporated by reference, plus legal and auditor consents.
Oragenics, Inc. filed a Current Report on Form 8-K dated August 11, 2025 stating the company issued a press release updating shareholders on developments in the second quarter of 2025 and shortly thereafter. The filing expressly attaches that press release as Exhibit 99.1 and includes the cover page Interactive Data File as Exhibit 104.
The 8-K lists Oragenics' state of incorporation as Florida, its trading symbol OGEN on NYSE American, the principal executive office address and phone number, and is signed by CEO Janet Huffman. The body of the filing notifies investors of the press release but does not include additional financial or operational detail beyond the exhibits referenced.
Oragenics, Inc. reported a consolidated net loss of $4.49 million for the six months ended June 30, 2025, and an accumulated deficit of $221.3 million. Cash and cash equivalents were $1.97 million at June 30, 2025. The company effected a 1-for-30 reverse stock split on June 3, 2025, and its independent auditor included an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Operating expense trends show lower spend year-over-year: research and development fell ~49.6% to $791,221 for the six months and general and administrative declined ~7.7% to $2.95 million, resulting in total operating expenses of $3.74 million (down ~21.5%). Financing activity included net proceeds of $2.6 million from ATM sales in February 2025, a $3.0 million promissory note issued March 13, 2025 (subsequently repaid), and a July 2, 2025 public offering of Series H Convertible Preferred Stock and warrants that produced net proceeds of approximately $15.2 million, which the company states extends its cash runway into the first half of 2026. The filing discloses a pending dispute with Ladenburg Thalmann and anti-dilution provisions in the Series H terms.